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Abstract
Background: Hormonal therapy (HT) either estrogen alone (E-alone) or estrogen plus progesterone (E+P) appears to
increase the risk for breast cancer in Western countries. However, limited information is available on the association
between HT and breast cancer in Asian women characterized mainly by dietary phytoestrogens intake and low prevalence
of contraceptive pills prescription.
Methodology: A total of 65,723 women (20–79 years of age) without cancer or the use of Chinese herbal products were
recruited from a nation-wide one-million representative sample of the National Health Insurance of Taiwan and followed
from 1997 to 2008. Seven hundred and eighty incidents of invasive breast cancer were diagnosed. Using a reference group
that comprised 40,052 women who had never received a hormone prescription, Cox proportional hazard models were
constructed to determine the hazard ratios for receiving different types of HT and the occurrence of breast cancer.
Conclusions: 5,156 (20%) women ever used E+P, 2,798 (10.8%) ever used E-alone, and 17,717 (69%) ever used other
preparation types. The Cox model revealed adjusted hazard ratios (HRs) of 2.05 (95% CI 1.37–3.07) for current users of E-
alone and 8.65 (95% CI 5.45–13.70) for current users of E+P. Using women who had ceased to take hormonal medication for
6 years or more as the reference group, the adjusted HRs were significantly elevated and greater than current users and
women who had discontinued hormonal medication for less than 6 years. Current users of either E-alone or E+P have an
increased risk for invasive breast cancer in Taiwan, and precautions should be taken when such agents are prescribed.
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Introduction
Many studies have shown that hormonal therapy (HT) with
estrogen plus progesterone (E+P) increases the risk for breast
cancer [1–5]. In particular, the results of the observational Million
Women Study (MWS) [2] and the Nurses’ Health Study (NHS) [6]
suggest that there is an association between estrogen and breast
cancer in routine gynaecology practices [7]. By contrast, the
Women’s Health Initiative (WHI) [1] did not detect a higher level
of risk in the estrogen alone (E-alone) group. Unfortunately, long-
term randomised controlled trials that are designed to assess the
above inconsistent findings appear to be difficult due to ethical,
economical, and practical considerations [7]. Besides, most studies
[1–6,8], have not deliberately controlled the factor of herbs
consumption [9], which may contain estrogen-like substances [10–
14] and are increasingly widely used in women [15,16]. All the
above factors leave lots of space for more studies. Large-scale
retrospective data can help to assess the association between breast
cancer and HT in real practice. We excluded women ever
prescribed traditional Chinese medicines and compared hazard
ratios for breast cancer across categories of different types of HT in
a large retrospective Taiwan cohort.
Results
The database contained a total of 2,461 prevalent cases of
invasive breast cancer that were diagnosed between 1997 and
2008. Within this population, we identified 780 patients who
were newly diagnosed with invasive breast cancer during the
ten-year study period (1999–2008) and were between the ages of
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e2518320 and 79 years. Table 1 summarises the characteristics of the
study population, the number of incidents of invasive breast
cancer, and the proportion of ever users of HT at baseline
according to the patient age. The proportion of different types
of HT varied substantially according to different age groups: E-
a l o n eH Tw a su s e dm a i n l yb yw o m e na g e d4 0t o5 9y e a r s ,E +P
H Tm a i n l yb yw o m e na g e d3 0t o4 9y e a r s ,a n do t h e rt y p e so f
H Tb yw o m e na g e d2 0t o3 9y e a r s .T h em a j o r i t yo fE - a l o n eH T
use comprised conjugated equine estrogen, and 0.625 mg/day
was the dose that was most commonly prescribed. Combination
therapy was frequently prescribed in a sequential manner that
usually constituted a combination of 0.625 mg conjugated
equine estrogen, and medroxyprogesterone acetate comprised
the great majority of all progesterone use. The average
prescribed cumulated estrogen doses of HT for the E-alone
HT, the mixed regimen (E-alone and E+P), and the E+PH T
group were 281.0, 297.3, and 170.8 mg, respectively. The
a v e r a g ea g eo ft h ew o m e na tt h et i m eo fr e c r u i t m e n tw a s
40.5615.2 years.
In comparison to women aged 30 to 39 years, the hazard ratios
(HRs) for invasive breast cancer among never users of HT were
1.88 (95% CI 1.49–2.37) for women aged 40 to 49 years and 1.73
(95% CI 1.32–2.26) for women aged 50 to 59 years. The HR
calculated from the Cox regression model for ever users of HT was
significantly higher than that determined for never users. Table 2
summarises the different magnitudes of invasive breast cancer risks
for the different types of HT (E-alone, E+P, E-alone and E+P
combination, and progesterone-alone) after adjusting for age. The
adjusted HR for the development of invasive breast cancer was
significantly increased by 2.03-fold (95% CI 1.36–3.05) for current
users of E-alone HT, by 2.67-fold (95% CI 1.75–4.06) for current
users of mixed regimen, but it was even higher for E+P (HR 8.72,
95% CI 5.50–13.82). The magnitudes of HR were higher if we
limited the analysis to postmenopausal women (55–79 years of
age). Such effects decreased markedly if the women no longer
received medications containing estrogens. In general, the HR
dropped to a risk near baseline when the medications had not been
used for more than 5 years.
When the reference group comprised women who ceased the
intakeofhormonalmedicationfor6yearsormore,theadjustedHRs
werestill significantlyelevated anddemonstrated greater magnitudes
than current users and women who ceased the intake of hormonal
medication for lessthan 6 years,and the effectof age was maintained
(Table3).Inparticular,the riskforinvasivebreastcancer inE+Pw a s
also higher than that in E-alone. When we limited the analysis to
current users (namely those who were prescribed HT within one
year before the diagnosis of breast cancer or at the end of 2008), a
statistically significant (P,.001) linear dose–response relationship
was observed between the risk for the development of invasive breast
cancer and the prescribed dose of E-alone, mixed regimen and E+P
HT.ThecomparisonofcurrentHTuserstowomenwhohad ceased
to use HT at least five years prior revealed that an increase of every
30 defined daily dose of E-alone, mixed regimen or E+PH Tw a s
significantly associated with an increased hazard ratio for invasive
breast cancer among current HT users.
Discussion
To our knowledge, this is the first study to employ a nation-wide
representative cohort to examine the increased risk for invasive
breast cancer among women in Taiwan who are undergoing
treatment with HT. Because this issue has been heavily debated
internationally, we must be cautious about potential confounding
factors prior to generating any inferences. However, the following
arguments provide a warning to individuals concerning the
possible risks of HT. First, because the NHIRD collects all
prescription information prospectively, we can rule out the
possibility of a recall bias concerning intake dosages and different
types of prescriptions: E-alone, E+P HT, progesterone only, or a
mixed regimen. Second, in the present study, we included all of
the patients who were newly diagnosed with invasive breast cancer
between 1999 and 2008 from a simple random sample of one
million subjects among the insured general population. Because
the rate of insured individuals has been consistently above 96%
since 1997, we can rule out the possibility of a selection bias. In
fact, our current estimate of 63.7 new breast cancer cases per
Table 1. Baseline demographic and clinical characteristics of the Taiwanese cohort (n=65,723) stratified by different types of
hormone replacement therapy followed from 1997 to 2008.
Characteristic Never users E-alone E+P E-alone and E+P P-alone
Total No. 40,052 5,156 2,798 9,961 7,756
New breast cancer, No. (%) 497(1.2) 69(1.3) 41(1.5) 106(1.1) 67(0.9)
Incidence rate
+ 103.4 111.5 122.1 88.7 72.0
Mean (SD) age at inclusion, years 41.9(16.1) 48.6(13.1) 44.0(14.4) 37.8(12.2) 30.7(8.3)
Age groups at inclusion, years No. (%)
20–29 11,171(27.9) 434(8.4) 548(19.6) 3,033(30.5) 3,970(51.2)
30–39 9,931(24.8) 732(14.2) 618(22.1) 2,714(27.3) 2,748(35.4)
40–49 7,049(17.6) 1,741(33.8) 621(22.2) 2,614(26.2) 889(11.5)
50–59 4,398(11.0) 1,164(22.6) 552(19.7) 1,011(10.2) 59(0.8)
60–69 4,556(11.4) 717(13.9) 344(12.3) 449(4.5) 54(0.7)
70–79 2,947(7.4) 375(7.3) 119(4.3) 140(1.4) 36(0.5)
Cumulative estrogen dose, mean (SD), DDD 0 281.0(714.7) 170.8(427.3) 297.3(686.3) 0
Cumulative progesterone dose, mean (SD), DDD 0 0 139.5(407.1) 148.4(545.1) 128.9(7177.0)
*E+P, estrogen-progesterone combination; E-alone, estrogen-alone; P-alone, progesterone only; E-alone and E+P ( the mixed regimen), combinations of the above types
(E+P, E-alone); DDD, defined daily dose.
+Average annual per 100,000.
doi:10.1371/journal.pone.0025183.t001
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person-years that was calculated from the National Cancer
Registry of Taiwan in 2005. Third, to minimise potential
confounding factors according to the indication, we limited the
analysis to postmenopausal women (55–79 years old of age), and
an association between HT and invasive breast cancer risk was still
observed, as summarised in Table 2. Indeed, this direct effect of
age on breast cancer risk corroborates the result obtained in
previous studies [17,18]. Fourth, we attempted to control for
potential confounding factors associated with the indication by
evaluating ex-users who had ceased hormone medication intake
for 6 years or more as the reference group. Table 3 shows that a
discontinued exposure to HT significantly decreases the risk for
invasive breast cancer among women of both reproductive age
and postmenopausal age, and there is a consistent trend that
demonstrates a decreased risk that is accompanied by a longer
period of discontinued exposure. Moreover, a significant linear
dose-response relationship was observed for an increment of 30
defined daily doses among current users in comparison with ex-
users who had ceased HT for more than 6 years. Because we
minimized the risk for data falsification, we tentatively concluded
that in Taiwan, current users of E-alone and/or E+P HT might
have an increased risk for invasive breast cancer.
The present findings shown in Tables 2 and 3 corroborate the
results of the WHI, which demonstrated that estrogen plus
progesterone might be associated with an increased risk for breast
cancer. Although this study was not a randomised control trial, it
included a cohort of one million random samples that has been
shown to be representative of the population in Taiwan. Since the
WHI published their major findings in 2002, Taiwanese women
have demonstrated a period of reduced prescription hormone
intake [19]. In fact, due to fear of any challenge from the patient
and/or her family, physicians typically do not prescribe hormones
to any patient if there is any doubt regarding the possible
beneficial or potential harmful effects of hormones [20,21].
Moreover, the National Health Insurance in Taiwan stipulates a
three-month upper limit for repeat prescriptions, which provides
another constraint on any unnecessary or harmful medications.
The frequency of HT prescribing in Taiwan was somewhat
expected lower than in the United States due to this HT
prescribing policy (Table S1). As shown in Tables 2 and 3, a
positive association between E+P and the occurrence of invasive
breast cancer in women in Taiwan was still observed under the
above circumstances, we think that such a positive association is
real.
Breast cancer incidence was notably high in Western countries
and the rates of all age groups exceeded those from Taiwan,
Japan, and Hong Kong (Table S2). Although the WHI and some
studies in Western countries [22–24] did not observe a positive
association between breast cancer and an estrogen exposure of less
Table 2. Number (No.) of new cases, population-at-risk, and estimated hazard ratios (HR), 95% confidence intervals (CI) based on
multivariate Cox regression model on a random sample of the National Health Insurance Research Database followed from 1997 to
2008 stratified by age in 1997.
Women aged 20 to 79 years Women aged 55 to 79 years
HRT use at baseline No. Cases/population HR(95% CI) No. Cases/population HR(95% CI)
Never users (referents) 497/40,052 1 124/9,939 1
Estrogen-alone
Current users 25/656 2.03(1.36–3.04) 6/135 3.13(1.37–7.12)
Last use 1–3 years previously 18/815 1.22(0.76–1.96) 7/199 2.58(1.20–5.53)
Last use 4–5 years previously 11/832 0.73(0.40–1.33) 4/242 1.21(0.45–3.27)
Last use .=6 years previously 15/2,853 0.29(0.17–0.49) 6/1,072 0.43(0.19–0.97)
Estrogen-progesterone combination
Current users 19/196 8.74(5.52–13.86) 11/23 51.64(27.74–96.11)
Last use 1–3 years previously 7/329 2.16(1.02–4.55) 5/26 16.95(6.91–41.58)
Last use 4–5 years previously 6/394 1.35(0.60–3.03) 2/32 4.54(1.12–18.38)
Last use .=6 years previously 9/1,879 0.27(0.14–0.53) 3/642 0.34(0.11–1.06)
Others
Estrogen-alone and Estrogen-progesterone combination
Current users 51/2,065 2.01(1.50–2.68) 4/133 2.00(0.73–5.43)
Last use 1–3 years previously 23/2,215 0.92(0.61–1.40) 2/119 1.17(0.29–4.74)
Last use 4–5 years previously 17/1,895 0.68(0.42–1.10) 2/156 0.90(0.22–3.65)
Last use .=6 years previously 15/3,786 0.26(0.16–0.44) 1/584 0.12(0.02–0.88)
Progesterone-alone
Current users 14/766 2.78(1.63–4.77) 0/13 -
Last use 1–3 years previously 15/1,311 1.71(1.02–2.88) 0/26 -
Last use 4–5 years previously 12/1,421 1.19(0.67–2.13) 0/25 -
Last use .=6 years previously 26/4,258 0.70(0.47–1.04) 0/47 -
*HRT, hormone replacement therapy; Other types, including mixed combinations of the above types (estrogen-progesterone combination, estrogen-alone) and
progesterone only.
doi:10.1371/journal.pone.0025183.t002
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hypothesis. As Asian women are generally slimmer than women
from Western countries, they might be exposed to a relatively high
dose of estrogen based on the guideline recommendations. Given
the 12 years of follow-up that were available for testing this
hypothesis, we were more likely to detect a positive effect between
the prescription of E-alone and invasive breast cancer. Under the
NHI system in Taiwan, all individuals who receive HT are
required to undergo a follow-up by their physicians no longer than
three months. These guidelines increase the likelihood of breast
cancer detection during an earlier stage of disease rather than
during the invasive stage [25]. The positive association persisted
under the following different settings. When we limited our
analysis to postmenopausal women, or when women who have
ceased to use E-alone for more than 6 years were used as the
reference group, a positive linear dose-response relationship was
observed among current users (Table 3). Considering evidence
obtained in observational studies that were conducted in Western
countries, we suspect that this association is real with respect to the
prescribed doses administered in women in Taiwan. As the
prevalence of HT exposure differs between Taiwan and other
countries, however, we would also expect the burden of HT
attributable cancer incidence to differ across the countries, which
is of potential interest for public health policy makers. This
observation warrants further studies to determine whether a
differential genetic susceptibility between Asian and Caucasian
postmenopausal women and the use of universal precautions.
In this study and others [26], the combined estrogen-
progesterone regimen appeared to be a maximally effective type
of estrogen in regard to the occurrence of breast cancer beyond
which other types of HT regimens had no or less effect. Adding a
progesterone to an estrogen therapy was associated with greater
increases in breast cancer risk and with longer washout period for
reducing the residual effects compared with the use of estrogen
alone. Just as importantly, the disparity between the associations
became even larger when we limited our analysis to postmeno-
pausal women. We hypothesize that progesterone play an
important role on the occurrence of breast cancer especially in
whom has relatively lower endogenous estrogen levels. And,
further analysis found that women use mixed regimen were no
Table 3. Number (No.) of new cases, population-at-risk, and estimated hazard ratios (HR), 95% confidence intervals (CI) estimated
from multivariate Cox regression model on a random sample of the National Health Insurance Research Database among women
with hormone replacement therapy stratified by age and followed from 1999 to 2008.
Women aged 20 to 79 years Women aged 55 to 79 years
HRT use at baseline No. Cases/population HR(95% CI) No. Cases/population HR(95% CI)
Estrogen-alone
Last use .=6 years previously 15/2,853 1.00 6/1,072 1.00
Last use 4–5 years previously 11/832 2.65(1.21–5.79) 4/242 2.93(0.82–10.40)
Last use 1–3 years previously 18/815 4.47(2.24–8.92) 7/199 5.94(1.99–17.68)
Current users 25/656 7.73(4.02–14.84) 6/135 7.74(2.47–24.23)
Per 30 DDD - 1.07(1.04–1.09) - 1.16(1.05–1.28)
Estrogen-progesterone combination
Last use .=6 years previously 9/1,879 1.00 3/642 1
Last use 4–5 years previously 6/394 9.69(3.40–27.67) 2/32 13.85(2.31–83.00)
Last use 1–3 years previously 7/329 14.50(5.26–40.01) 5/26 43.52(10.20–185.79)
Current users 19/196 61.89(27.37–139.96) 11/23 143.90(39.90–518.96)
Per 30 DDD - 1.40(1.29–1.51) - 1.71(1.50–1.95)
Others
Estrogen-alone and Estrogen-progesterone combination
Last use .=6 years previously 15/3,786 1 1/584 1
Last use 4–5 years previously 17/1,895 2.71(1.35–5.44) 2/156 7.09(0.64–78.22)
Last use 1–3 years previously 23/2,215 3.80(1.97–7.34) 2/119 9.51(0.86–105.20)
Current users 51/2,065 8.18(4.58–14.62) 4/133 14.58(1.62–131.26)
Per 30 DDD - 1.09(1.05–1.12) - 1.12(1.06–1.19)
Progesterone-alone
Last use .=6 years previously 26/4,258 1 0/47 -
Last use 4–5 years previously 12/1,421 1.82(0.92–3.63) 0/25 -
Last use 1–3 years previously 15/1,311 2.59(1.36–4.94) 0/26 -
Current users 14/766 4.32(2.22–8.38) 0/13 -
Per 30 DDD - - - -
*HRT, hormone replacement therapy; Other types, including mixed combinations of the above types (estrogen-progesterone combination, estrogen-alone) and
progesterone only.
With last use of hormones more than 6 years ago as the referents, we tested different periods of last use and the potential dose-response relationship with an increment
of 30 DDD (defined daily dose) among current users.
doi:10.1371/journal.pone.0025183.t003
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either in reproductive or in postmenopausal age group. The
evidence we obtained indicated that the particular type of HT,
adding a progesterone continuously to a postmenopausal hormone
program, will be more likely to increase the occurrence of breast
cancer. However, before drawing any conclusions from the data,
further studies are warranted to be replicated with a larger sample
size.
The present study has some limitations. First, because the
identities of the patients were not available in the NHI
reimbursement database, we were unable to obtain any histopa-
thology reports to verify the diagnoses. However, because approval
for the registration of invasive breast cancer as a catastrophic
illness is based on pathology and/or cytologic evidence and is
followed by a full waiver of copayment, such a diagnosis is made
only after very serious considerations and is generally accurate.
The diagnostic accuracy of invasive breast cancer among the NHI
data is corroborated by the considerable agreement between the
incidence rate calculated herein and that determined by the
National Cancer Registry of Taiwan, in which 95% of the breast
cancers are accompanied by histopathologic validation. Second,
we were unable to contact the patients directly regarding their use
of HRT due to the encryption of their identification numbers;
therefore, we cannot exclude the possibility that the subjects used
additional phytoestrogenic herbs that were not prescribed.
However, because the NHI system provides a comprehensive
coverage and because the copayment for prescriptions is
consistently 50 NT$ (New Taiwan Dollar) (approximately equal
to US $1.5), which is generally less than the cost of herbs that are
sold in the markets of Taiwan, the likelihood that the subjects
purchased a large amount of other phytoestrogen-containing herbs
outside of the NHI database is low. Furthermore, because we had
previously limited the cohort to women who did not receive
prescription Chinese herbal products during the 12 years of
observation, the likelihood that the subjects purchased herbs
outside of the services of the NHI becomes even lower.
Furthermore, when we limited our analysis to postmenopausal
women (55 to 79 years of age) who did not require post-coitus
emergency contraceptives or birth control pills, the results showed
the same trend as that observed among women aged between 20
to 79 years. However, we are unable to rule out the possibility that
the occurrence of breast cancer in postmenopausal women was
attributed by the use of a contraceptive pill early in life. Third, we
were unable to validate the actual ingested dose of the prescribed
HT recorded in the database. A large mean cumulative dose
indicates that the patient continued to receive the same
prescription for a long period and implies that the patient actually
consumed the prescribed medication. Even if the patient did not
consume all of the prescribed HT pills, the present findings would
only underestimate the effect of the consumed HT. Fourth,
because the reimbursement data did not include the selection
patterns of phytoestrogen-rich foods, the relative weight and
reproductive history of the women, we were unable to control for
this factor in the model construction. Because the present study
included females from a random sampling cohort, we assumed
that such confounding factors would not bias the results.
In summary, the present study found that current users of
carefully prescribed E-alone or E+P in Taiwan have an increased
risk for invasive breast cancer, especially elderly women. The
overall risk seems to be less favourable for E+P in comparison to
E-alone. Thus, we recommend that precautionary actions be taken
toward the prescription of HT for any duration among
postmenopausal women in Taiwan, and the current findings
should be incorporated into the established guidelines and
emerging risks and benefits of these agents.
Materials and Methods
Ethics statements
This study was initiated after approval by the review board of
the Committee on Chinese Medicine and Pharmacy, Department
of Health, Taiwan. All data were obtained from the NHI
reimbursement database. The National Health Research Institutes
of Taiwan anonymized and transformed the NHI reimbursement
data as files suitable for research. Since the identification numbers
and personal information of all individuals were not included in
the above secondary files to protect the privacy of the individuals,
the review board approved that written consents from patients
were not required.
Study population and data collection
In March of 1995, Taiwan established the National Health
Insurance (NHI) programme, which routinely reimburses more
than 96% of Taiwanese residents [27] for the cost of prescribed
medicines since 1997. All reimbursement data for the NHI that
are transformed and maintained by the National Health Research
Institutes (NHRI) of Taiwan [28] contained detailed demographic
data (including birth date and sex) and information regarding
health-care services provided for each patient, including all of the
payments for outpatient visits, hospitalisations, and prescriptions,
and the residence of each patient. The data also contained that
were documented for each outpatient visit or hospitalisation
included up to five diagnoses that were coded according to the
International Classification of Diseases, Ninth Revision (ICD-9 ) [29], all of
the drugs prescribed and their doses (i.e., conventional medicines,
including generic and commercial brands of estrogen and
progesterone drugs, and Chinese herbal medicines (CHM)), and
the date of each prescription. To facilitate research, the NHRI has
created a simple random sample of one million individuals from
the 22 million insured populations (National Health Insurance
Research Database) which cohort was further validated to be
representative of the entire insured population [28].
The selection of study subjects from the random sample of one
million individuals was performed as follows (Figure 1). First, we
excluded all of the male subjects (n=495,836) or those with
missing information concerning gender (n=3). Age was calculated
by subtracting the subject’s birthday from the 1
st day of July for
each year. Second, subjects under 20 (n=193,511) or over 79
years of age (n=2,242) were excluded to limit the study sample to
the main consumers of hormones in Taiwan. All of the patients
with invasive breast cancer were included in the study, and the
diagnosis was verified by the NHI catastrophic illnesses registry
during 1998-2008. Because all patients who are confirmed to have
a catastrophic illness are exempt from all copayments, the
presence of invasive breast cancer must be validated by tissue
pathology to qualify for the registry, and the case is further
classified into one of the following categories: the nipple and areola
(ICD-9 codes 1740); central portion; upper-inner quadrant; lower-
inner quadrant; upper-outer quadrant; lower-outer quadrant;
axillary tail; unspecified (ICD-9 code 1741, 1742, 1743, 1744,
1745, 1746, and 1749, respectively); other specified sites of the
female breast (ICD-9 code 1748). We excluded two years, 1997
and 1998, to avoid the inclusion of 1926 prevalent cases. To
control potential confounding factors, we further excluded 850
subjects who had ever used tamoxifen prior to any diagnosis of
breast cancer. Finally, 305,633 subjects qualified for inclusion in
the cohort. 10,309 Chinese herbal products (CHPs) were licensed
Breast Cancer Associated with Hormonal Therapy
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Chinese herbal products (CHP) contain small amounts of
estrogen-like substances [10-14,30] and are prescribed frequently
in Taiwan, e.g., dong quai, ginseng , licorice, and ge gen, among
others. Thus, we further excluded 239,910 subjects who had ever
used CHP to make sure the results will not be biased by its
inconclusive effects on breast cancer as shown in Table 4. Finally,
we obtained a reference group of 40,052 subjects who had not
used CHP or hormones during the study period and three exposed
groups with demonstrated different types of hormone usage (5,156
prescribed E-alone, 2,798 E+P, and 17,717 others).
Exposure assessment for HT
A total of 25,671 women were prescribed at least one type of HT
without an additional intake of any Chinese herbs during the study
period from January 1, 1997 to December 31, 2008. All of the
prescribed medications were covered under the NHI of Taiwan,
and no drugs were dispensed at a pharmacy without a physician’s
prescription. The major indications for E-alone and E+P in women
were contraception, dysmenorrhoea, hypogonadism (estrogen-
deficient patients), menopausal hot flashes, and vaginal atrophy.
The reimbursement database contained all the details regarding the
prescribed conventional medicines, which included all of the types
ofHT andthecommercialnamesof 14types ofestrogen-containing
drugs and ten types of progestagen-containing drugs. The variables
for HT usage that were included in the analyses were defined
according to the specific proprietary preparation of HT used by the
subjects during the 12-year study period. We categorised the types
of preparations used as follows: E-alone; E+P; other preparations,
including progesterone only and vaginal and other local treatments;
combinations of the above preparation types.
Statistical analyses
The incidence rate was summarised as the number of new
invasive breast cancer patients/10
6 person-years at risk. Using
40,052 non-hormone users as the reference group, we constructed
multivariateCoxproportionalhazardmodelstoestimatethehazard
ratios and their 95% confidence intervals (CI) for new occurrences
of invasive breast cancer after adjusting for age. To minimise the
potential confounding by indications for HT, we conducted another
Cox regression using women who had ceased prescription hormone
intakefor6 years ormore asthe referencegroup.An estimate with a
95% CI that did not contain the number 1 was considered
statistically significant. All the above analyses were conducted using
the SAS ver. 9.2 software package (SAS Institute, Cary, NC, USA).
Figure 1. Algorithm of recruitment of subjects into the cohort
from the one million random sample of the National Health
Insurance Research Database (NHIRD) followed from 1997 to
2008 in Taiwan.
doi:10.1371/journal.pone.0025183.g001
Table 4. Distribution frequencies of licensed and prescribed Chinese herbal products containing estrogen-like substance, 1999–
2008*.
Chinese herbal products No. of licensed Major Corresponding (Metabolic) Active Substance(s) in Humans
Total licensed Chinese herbal products 10,309 (100)
Dong Quai 2,492 (24.2) estrogen-like effect
Ginseng 1,960 (19.0) estrogen-like effect
Licorice 5,342 (51.8) estrogen-like effect
Licensed Chinese herbal products containing estrogen-like
substance
721 (7.0)
Psoraleae Fructus 60 (0.6) Genistein, daidzein and biochanin A, coumestrol
Puerariae Radix 505 (4.9) Puerarin, daidzin, genistin, daidzein and genistein, coumestrol
Sojae Semen Praeparatum 74 (0.7) Genistein, genistin, daidzein, daidzin, glycitein and glycitin, coumestrol
Sophorae Flavescentis Radix 75 (0.7) Daidzein, genistein and formononetin
Sophorae Immaturus Flos 38 (0.4) Genistin, genistein
*The table shows the distribution frequencies of licensed and prescribed Chinese herbal products (CHPs) that may contain estrogen-like substance.
doi:10.1371/journal.pone.0025183.t004
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